Privately-held pharma company Novaliq GmbH said this week that its NovaTears+Omega-3 combo therapy for patients with evaporative dry disease was registered in Europe. The treatment uses Novaliq’s water-free EyeSol drug delivery tech and is available in a multi-dose bottle. The company touted its product as the first eye drop to contain high concentrations of Omega-3 ethyl ester. […]
Novaliq GmbH
Novaliq’s NovaTears dry eye disease therapy launches in New Zealand
Novaliq today launched its dry eye disease therapy, NovaTears, in New Zealand and said that it won registrational approval in Australia. The Germany-based company inked an exclusive licensing partnership earlier this year with AFT Pharmaceuticals (ASX:AFP) to commercialize Novaliq’s water-free topical eye drops in Australia. Get the full story at our sister site, Drug Delivery Business News.
Novaliq, AFT Pharmaceuticals ink licensing deal for NovaTears dry eye therapy
Ocular therapeutics company Novaliq said today that it inked a strategic licensing agreement with AFT Pharmaceuticals for the commercialization of its dry eye therapy, NovaTears, in Australia and New Zealand. NovaTears is the Germany-based company’s 1st commercially available product indicated for the treatment of evaporative dry eye diseases. Get the full story at our sister site, Drug […]
Ocular therapeutics company Novaliq names new CEO
Novaliq GmbH said yesterday that it named Christian Roesky as its new CEO, replacing co-founder Bernhard Günther, who will take on a new role as chief innovation officer. The Heidelberg, Germany-based company focuses on renovating poorly soluble drugs into effective ocular therapeutics. Its CE-marked product, NovaTears, was developed from its proprietary EyeSol technology. With its […]